Previous Study: TRIO023
Next Study: TRIO025

Studies & Results


A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer

View FDA Study View EU Study


ASCO Annual meeting, 2015

Turner NC, Balmaña J, Fasching PA, et al

A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).

SABCS 2017

Hurvitz S, et al.

Health-related quality of life during a phase 2 study of talazoparib in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO)

SABCS 2017

Telli ML, et al.

ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial.

ESMO Congress 2019

Turner NC, et al.

Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations 

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at